

IMMUNOMEDICS INC  
Form 8-K  
October 15, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **October 15, 2009**

**Immunomedics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-12104**  
(Commission File Number)

**61-1009366**  
(IRS Employer Identification No.)

**300 American Road, Morris Plains, New Jersey**  
(Address of principal executive offices)

**07950**  
(Zip Code)

Registrant's telephone number, including area code: **(973) 605-8200**

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On October 15, 2009, Immunomedics, Inc., a Delaware corporation (the "Company"), issued a press release announcing further topline results for epratuzumab Phase IIb study in systemic lupus erythematosus (SLE). The full text of the press release is attached to this current report on

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

Form 8-K as Exhibit 99.1 hereto and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Immunomedics, Inc. dated October 15, 2009 announcing further topline results for epratuzumab Phase IIb study in systemic lupus erythematosus (SLE).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**October 15, 2009**

---

(Date)

**Immunomedics, Inc.**

---

(Registrant)

**/s/ CYNTHIA L. SULLIVAN**

---

Cynthia L. Sullivan  
*President and Chief Executive Officer*